It must be appreciated that bromocriptine has been demonstrated to affect several other central pathways that can act to improve glucose intolerance such as reducing elevated VMH serotonin levels, as well as reducing elevated paraventricular nucleus norepinephrine, neuropeptide Y and corticotropin releasing factor levels,4, 11, 42 each of which could contribute to the bromocriptine impact on VMH glucose sensing observed herein, as previously discussed.6, 8. This evidence concerns the gene CRH and Glucose intolerance.